IQ EQ FUND MANAGEMENT IRELAND Ltd Grows Stock Holdings in Intellia Therapeutics, Inc. $NTLA

IQ EQ FUND MANAGEMENT IRELAND Ltd boosted its stake in shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA) by 68.0% during the 3rd quarter, HoldingsChannel reports. The institutional investor owned 494,468 shares of the company’s stock after purchasing an additional 200,081 shares during the quarter. IQ EQ FUND MANAGEMENT IRELAND Ltd’s holdings in Intellia Therapeutics were worth $8,539,000 at the end of the most recent reporting period.

Several other institutional investors have also modified their holdings of NTLA. AQR Capital Management LLC grew its holdings in shares of Intellia Therapeutics by 154.1% in the 1st quarter. AQR Capital Management LLC now owns 90,875 shares of the company’s stock worth $646,000 after acquiring an additional 55,118 shares during the period. Woodline Partners LP acquired a new position in shares of Intellia Therapeutics during the 1st quarter worth $171,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its position in shares of Intellia Therapeutics by 8.0% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 521,706 shares of the company’s stock worth $3,709,000 after buying an additional 38,521 shares in the last quarter. Cyndeo Wealth Partners LLC purchased a new position in Intellia Therapeutics during the 2nd quarter valued at about $101,000. Finally, CWM LLC raised its position in Intellia Therapeutics by 22.9% during the second quarter. CWM LLC now owns 18,331 shares of the company’s stock worth $172,000 after acquiring an additional 3,419 shares during the last quarter. Hedge funds and other institutional investors own 88.77% of the company’s stock.

Intellia Therapeutics Stock Down 10.3%

Shares of NTLA opened at $11.09 on Friday. The firm has a market cap of $1.28 billion, a PE ratio of -2.60 and a beta of 2.10. The company’s fifty day moving average is $10.75 and its two-hundred day moving average is $12.97. Intellia Therapeutics, Inc. has a fifty-two week low of $5.90 and a fifty-two week high of $28.25.

Intellia Therapeutics (NASDAQ:NTLA) last issued its earnings results on Thursday, November 6th. The company reported ($0.92) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.02) by $0.10. The firm had revenue of $13.78 million for the quarter, compared to analysts’ expectations of $14.12 million. Intellia Therapeutics had a negative return on equity of 57.01% and a negative net margin of 774.94%.The firm’s revenue for the quarter was up 51.6% compared to the same quarter last year. During the same quarter last year, the firm earned ($1.34) earnings per share. As a group, equities research analysts anticipate that Intellia Therapeutics, Inc. will post -5.07 earnings per share for the current year.

Insider Buying and Selling

In related news, CEO John M. Leonard sold 34,146 shares of the stock in a transaction that occurred on Monday, January 5th. The shares were sold at an average price of $9.21, for a total transaction of $314,484.66. Following the completion of the sale, the chief executive officer owned 1,013,339 shares of the company’s stock, valued at approximately $9,332,852.19. This represents a 3.26% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP James Basta sold 10,397 shares of Intellia Therapeutics stock in a transaction that occurred on Monday, January 5th. The shares were sold at an average price of $9.21, for a total transaction of $95,756.37. Following the transaction, the executive vice president directly owned 101,528 shares in the company, valued at approximately $935,072.88. This trade represents a 9.29% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last quarter, insiders sold 53,051 shares of company stock valued at $488,600. 3.10% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

A number of research analysts have recently weighed in on NTLA shares. Wall Street Zen cut shares of Intellia Therapeutics from a “hold” rating to a “sell” rating in a research note on Sunday, January 18th. Citigroup reiterated a “market outperform” rating on shares of Intellia Therapeutics in a research report on Tuesday, October 28th. HC Wainwright raised their price target on shares of Intellia Therapeutics from $15.00 to $25.00 and gave the stock a “buy” rating in a research note on Wednesday, January 28th. JMP Securities cut their price objective on shares of Intellia Therapeutics from $33.00 to $29.00 and set a “market outperform” rating for the company in a research report on Tuesday, October 28th. Finally, Royal Bank Of Canada decreased their target price on shares of Intellia Therapeutics from $14.00 to $9.00 and set a “sector perform” rating on the stock in a research report on Friday, November 7th. Nine analysts have rated the stock with a Buy rating, nine have given a Hold rating and three have issued a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of $18.00.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc (NASDAQ: NTLA) is a clinical‐stage biotechnology company focused on developing potentially curative genome editing therapies using the CRISPR/Cas9 platform. The company’s research spans both in vivo and ex vivo applications of CRISPR/Cas9, aiming to correct or disable disease‐causing genes with a single administration. Intellia’s lead in vivo program targets transthyretin amyloidosis (ATTR) by delivering CRISPR/Cas9 machinery directly to the liver, while additional preclinical efforts pursue treatments for hemophilia A, hereditary angioedema and other genetic disorders.

Beyond its in vivo pipeline, Intellia collaborates with strategic partners to extend the impact of its genome editing approach.